LISBON, Portugal--(BUSINESS WIRE)--Ultra-long-acting insulin degludec, an investigational basal insulin being developed by Novo Nordisk, showed significant blood sugar reductions in patients with type 2 diabetes. A study demonstrated that changes in the injection time of insulin degludec from day to day (up to 40 hours apart) did not affect overall glycaemic control or risk of hypoglycaemia when compared to insulin glargine given at the same time each day. Data were presented today at the 47th meeting of the European Association for the Study of Diabetes (EASD) in Lisbon. The clinical investigation of insulin degludec is ongoing and regulatory submission has not been filed.
